Keymed Biosciences Inc. (HKG: 2162) announced that its NewCo partner Ouro Medicines has entered into a definitive merger agreement with Gilead Sciences (NASDAQ: GILD). Gilead will acquire Ouro Medicines for up to $2.175 billion ($1.675 billion upfront + $500 million milestones), with Keymed set to receive approximately $320 million ($250 million upfront + $70 million milestones) as a shareholder. The transaction accelerates global development of CM336/OM336, a potential best-in-class T-cell engager (TCE) for autoimmune diseases, with tiered royalties now fulfilled by Gilead.
Transaction Structure
Element
Detail
Acquirer
Gilead Sciences (NASDAQ: GILD)
Target
Ouro Medicines (NewCo established November 2024)
Total Deal Value
Up to $2.175 billion ($1.675B upfront + $500M milestones)
Keymed Stake
Shareholder of Ouro Medicines
Keymed Proceeds
~$250 million upfront + ~$70 million milestones = ~$320 million total
Post-Deal Equity
Keymed no longer holds equity in Ouro Medicines
Royalty Structure
Tiered royalties for CM336/OM336 now paid by Gilead (vs. Ouro Medicines previously)
Accelerated global development of CM336/OM336 as autoimmune TCE; Gilead immunology franchise expansion
Strategic Impact & Value Creation
Factor
Implication
Keymed Value Realization
$320 million cash infusion (vs. ~$180 million market cap pre-announcement) – transformational liquidity event for China biotech
Gilead Immunology Strategy
Acquires clinical-stage TCE platform to complement filgotinib (JAK) and expand into B-cell depletion autoimmunity (SLE, MS, myasthenia gravis)
CM336/OM336 Acceleration
Gilead’s global development infrastructure and regulatory expertise fast-tracks Phase II/III vs. NewCo standalone financing
Keymed China Retained Rights
Domestic TCE franchise preserved; potential for China-first approval and subsequent ex-China royalty stream from Gilead
NewCo Model Validation
Demonstrates asset monetization pathway for China biotechs: license to NewCo → Big Pharma acquisition → cash + royalty returns to originator
Keymed Post-Deal Position:~$320 million cash enables pipeline expansion (additional TCEs, ADCs); potential for special dividend or share buyback
Gilead Rationale: TCEs emerging as next-generation autoimmunity standard (following oncology success); CM336/OM336 provides differentiated B-cell targeting vs. CD19/CD20 monoclonals
Forward‑Looking Statements This brief contains forward‑looking statements regarding transaction closing timelines, milestone achievement, and global development progress for CM336/OM336. Actual results may differ due to regulatory approvals, clinical trial outcomes in autoimmune TCE applications, and Gilead’s portfolio prioritization decisions.-Fineline Info & Tech
By Fineline Cube